Literature DB >> 11810558

Comparative uptake of grepafloxacin and ciprofloxacin by a human monocytic cell line, THP-1.

T Hara1, H Takemura, K Kanemitsu, H Yamamoto, J Shimada.   

Abstract

The present study was designed to compare the uptake of grepafloxacin by a human monocytic cell line, THP-1, with that of ciprofloxacin. THP-1 cells were incubated with 20 microg/ml of either drug, and the entry of the drugs into the cells was determined using a velocity gradient centrifugation technique and HPLC assay. Antibiotic uptake by the cells was expressed as the ratio of the intracellular to the extracellular drug concentration (IC/EC). Grepafloxacin entered THP-1 cells readily within 5 min, and at steady-state (37 degrees C; 60 min), the IC/EC ratio of grepafloxacin (11.9 +/- 1.7; n = 13) was about 2.4-fold higher than that of ciprofloxacin (5.0 +/- 1.3; n = 13). The ratios decreased at low incubation temperature (4 degrees C), in paraformaldehyde-treated dead cells, and at low extracellular pH (pH 6.0), but were not influenced by high extracellular pH (pH, 9.0). Characterization of fluoroquinolone uptake suggests that these drugs penetrate the THP-1 membrane by passive diffusion, and also, in part, via an active transport system. We also examined the uptake of the two fluoroquinolones in phorbol 12 myristate 13-acetate (PMA)-stimulated adherent THP-1 cells (THP-1 macrophages). The IC/EC ratios for both fluoroquinolones in the THP-1 macrophages were significantly higher than those in the THP-1 monocytes. Further the uptake of three other fluoroquinolones, levofloxacin, tosufloxacin, and sparfloxacin, by THP-1 monocytes was examined in comparative studies. The IC/EC ratio of grepafloxacin was comparable to that of sparfloxacin and significantly higher than that of the other fluoroquinolones. Our results indicate that grepafloxacin exhibits better intracellular accumulation than ciprofloxacin and other fluoroquinolones in human monocytic and macrophage-like cells.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11810558     DOI: 10.1007/s101560070016

Source DB:  PubMed          Journal:  J Infect Chemother        ISSN: 1341-321X            Impact factor:   2.211


  5 in total

1.  Biopharmaceutical characterization of nebulized antimicrobial agents in rats: 1. Ciprofloxacin, moxifloxacin, and grepafloxacin.

Authors:  Aline Vidal Lacerda Gontijo; Julien Brillault; Nicolas Grégoire; Isabelle Lamarche; Patrice Gobin; William Couet; Sandrine Marchand
Journal:  Antimicrob Agents Chemother       Date:  2014-05-05       Impact factor: 5.191

2.  Influence of efflux transporters on the accumulation and efflux of four quinolones (ciprofloxacin, levofloxacin, garenoxacin, and moxifloxacin) in J774 macrophages.

Authors:  Jean-Michel Michot; Cristina Seral; Françoise Van Bambeke; Marie-Paule Mingeot-Leclercq; Paul M Tulkens
Journal:  Antimicrob Agents Chemother       Date:  2005-06       Impact factor: 5.191

3.  Characterization of the interactions between fluoroquinolone antibiotics and lipids: a multitechnique approach.

Authors:  Hayet Bensikaddour; Nathalie Fa; Ingrid Burton; Magali Deleu; Laurence Lins; André Schanck; Robert Brasseur; Yves F Dufrêne; Erik Goormaghtigh; Marie-Paule Mingeot-Leclercq
Journal:  Biophys J       Date:  2008-01-04       Impact factor: 4.033

4.  Treatment responses to Azithromycin and Ciprofloxacin in uncomplicated Salmonella Typhi infection: A comparison of Clinical and Microbiological Data from a Controlled Human Infection Model.

Authors:  Celina Jin; Malick M Gibani; Shaun H Pennington; Xinxue Liu; Alison Ardrey; Ghaith Aljayyoussi; Maria Moore; Brian Angus; Christopher M Parry; Giancarlo A Biagini; Nicholas A Feasey; Andrew J Pollard
Journal:  PLoS Negl Trop Dis       Date:  2019-12-26

5.  Intracellular Accumulation of Novel and Clinically Used TB Drugs Potentiates Intracellular Synergy.

Authors:  Lloyd Tanner; Gabriel T Mashabela; Charles C Omollo; Timothy J de Wet; Christopher J Parkinson; Digby F Warner; Richard K Haynes; Lubbe Wiesner
Journal:  Microbiol Spectr       Date:  2021-09-29
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.